orford-effectofhydrocortisone-2020.pdf (482.53 kB)
Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial
Version 2 2024-06-03, 17:35
Version 1 2020-11-17, 07:53
journal contribution
posted on 2024-06-03, 17:35 authored by DC Angus, L Derde, F Al-Beidh, D Annane, Y Arabi, A Beane, W Van Bentum-Puijk, L Berry, Z Bhimani, M Bonten, C Bradbury, F Brunkhorst, M Buxton, A Buzgau, AC Cheng, M De Jong, M Detry, L Estcourt, M Fitzgerald, H Goossens, C Green, R Haniffa, AM Higgins, C Horvat, SJ Hullegie, P Kruger, F Lamontagne, PR Lawler, K Linstrum, E Litton, E Lorenzi, J Marshall, D McAuley, A McGlothin, S McGuinness, B McVerry, S Montgomery, P Mouncey, S Murthy, A Nichol, R Parke, J Parker, K Rowan, A Sanil, M Santos, C Saunders, C Seymour, A Turner, F Van De Veerdonk, B Venkatesh, R Zarychanski, S Berry, RJ Lewis, C McArthur, SA Webb, AC Gordon, Neil OrfordNeil OrfordEffect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial
History
Journal
JAMA: Journal of the American Medical AssociationVolume
324Pagination
1317-1329Location
Chicago, Ill.Publisher DOI
Open access
- Yes
Link to full text
ISSN
0098-7484eISSN
1538-3598Language
EnglishPublication classification
C1 Refereed article in a scholarly journalIssue
13Publisher
American Medical AssociationUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC